- Home
- ESSA vs CGEN Comparison
ESSA vs CGEN Comparison
Compare ESSA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESSA
- CGEN
- Stock Information
- Founded
- ESSA 1916
- CGEN 1993
- Country
- ESSA United States
- CGEN Israel
- Employees
- ESSA N/A
- CGEN N/A
- Industry
- ESSA Banks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESSA Finance
- CGEN Health Care
- Exchange
- ESSA Nasdaq
- CGEN Nasdaq
- Market Cap
- ESSA 184.4M
- CGEN 167.4M
- IPO Year
- ESSA N/A
- CGEN 2000
- Fundamental
- Price
- ESSA $18.47
- CGEN $1.64
- Analyst Decision
- ESSA
- CGEN
- Analyst Count
- ESSA 0
- CGEN 0
- Target Price
- ESSA N/A
- CGEN N/A
- AVG Volume (30 Days)
- ESSA 18.6K
- CGEN 266.2K
- Earning Date
- ESSA 07-23-2025
- CGEN 08-05-2025
- Dividend Yield
- ESSA 3.25%
- CGEN N/A
- EPS Growth
- ESSA N/A
- CGEN N/A
- EPS
- ESSA 1.55
- CGEN N/A
- Revenue
- ESSA $66,345,000.00
- CGEN $27,589,000.00
- Revenue This Year
- ESSA $9.38
- CGEN N/A
- Revenue Next Year
- ESSA N/A
- CGEN $173.80
- P/E Ratio
- ESSA $11.93
- CGEN N/A
- Revenue Growth
- ESSA N/A
- CGEN N/A
- 52 Week Low
- ESSA $15.82
- CGEN $1.13
- 52 Week High
- ESSA $22.22
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- ESSA 48.52
- CGEN 54.29
- Support Level
- ESSA $18.62
- CGEN $1.65
- Resistance Level
- ESSA $19.08
- CGEN $1.83
- Average True Range (ATR)
- ESSA 0.37
- CGEN 0.10
- MACD
- ESSA -0.01
- CGEN -0.01
- Stochastic Oscillator
- ESSA 43.52
- CGEN 47.50
About ESSA ESSA Bancorp Inc.
ESSA Bancorp Inc is a holding company, engaged in accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in residential first mortgage loans (including construction mortgage loans), commercial real estate loans, home equity loans and lines of credit and commercial and industrial loans. The company offers a variety of deposit accounts, including checking, savings and certificates of deposit. The company also offers asset management and trust services and investment services. The company also offers insurance benefit consulting services through its wholly-owned subsidiary, ESSA Advisory Services, LLC.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.